Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $133,807.83 in Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) CFO Christopher Ryan Sullivan sold 7,979 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $16.77, for a total value of $133,807.83. Following the sale, the chief financial officer directly owned 25,318 shares in the company, valued at $424,582.86. This trade represents a 23.96% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Ryan Sullivan also recently made the following trade(s):

• On Thursday, April 2nd, Christopher Ryan Sullivan sold 7,980 shares of Avalo Therapeutics stock. The shares were sold at an average price of $17.15, for a total value of $136,857.00.

Avalo Therapeutics Price Performance

Shares of AVTX opened at $17.76 on Monday. Avalo Therapeutics, Inc. has a twelve month low of $3.39 and a twelve month high of $20.72. The stock has a market cap of $404.75 million, a PE ratio of -3.10 and a beta of 0.93. The business’s 50-day moving average price is $15.54 and its 200-day moving average price is $16.04.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($1.54) by $1.17. The firm had revenue of $0.06 million during the quarter, compared to the consensus estimate of ($0.21) million. Analysts expect that Avalo Therapeutics, Inc. will post -19.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Avalo Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its holdings in shares of Avalo Therapeutics by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock worth $552,000 after buying an additional 2,648 shares during the last quarter. Quadrature Capital Ltd bought a new stake in shares of Avalo Therapeutics during the 2nd quarter worth $55,000. Velan Capital Investment Management LP grew its position in Avalo Therapeutics by 38.4% in the second quarter. Velan Capital Investment Management LP now owns 154,972 shares of the company’s stock worth $773,000 after acquiring an additional 43,000 shares in the last quarter. Nantahala Capital Management LLC grew its position in Avalo Therapeutics by 10.6% in the second quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company’s stock worth $4,965,000 after acquiring an additional 95,000 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in Avalo Therapeutics by 7,066.8% in the second quarter. Bank of America Corp DE now owns 406,571 shares of the company’s stock valued at $2,029,000 after acquiring an additional 400,898 shares during the last quarter. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Guggenheim started coverage on shares of Avalo Therapeutics in a report on Monday, February 2nd. They issued a “buy” rating and a $50.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Friday, January 9th. Mizuho raised Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Wall Street Zen upgraded Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, March 29th. Finally, HC Wainwright upped their target price on Avalo Therapeutics from $25.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Avalo Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.25.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.